Kiniksa Pharmaceuticals, Ltd. (KNSA) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 beat expectations with EPS of $0.27 vs. $0.18 expected, ARCALYST revenue rose 56% YoY to $214.3M, 2026 ARCALYST revenue guidance was raised to $930M-$945M, and the stock is trading near 52-week highs.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity Strength ⢠Cash Generation ⢠Rich Valuation KNSA has a strong balance sheet and cash generation with decent profitability, but its rich valuation and heavy operating spend limit upside and margin of safety.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support defense ⢠Downtrend risk Support Level: $42.45 to $43.05 Resistance Level: $45.00 to $47.30 KNSA has weakened from an uptrend into a short-term downtrend over the last month, but holding the $42.45â$43.05 support zone could keep a bounce alive while a break below it would likely open more downside.
Sentiment & News
Key News Insights: ⢠52-week high ⢠Institutional buying ⢠Earnings catalyst Kiniksa Pharmaceuticals is seeing strong share momentum and growing visibility, driven by a new 52-week high, expanded institutional buying, ARCALYST marketing efforts, and an upcoming Q1 earnings catalyst.
AI Summary
KNSA has moved from a âproof-of-demandâ story to a premium-valued execution bet where ARCALYST growth and patient expansion can still drive upside, but the stock now depends heavily on flawless execution in one asset while leaving little margin for a commercial miss or slower-than-expected pipeline de-risking.
Description
Kiniksa Pharmaceuticals is a biopharmaceutical company that discovers, acquires, develops and commercializes therapies for patients with serious conditions lacking adequate treatment options. Its portfolio includes an approved interleukin-1 therapy for recurrent pericarditis and several monoclonal antibody candidates in clinical development for inflammatory and immune-mediated diseases. The company was incorporated in 2015 and is headquartered in Hamilton, Bermuda.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 29 | May 6 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Q1 2026 beat expectations with EPS of $0.27 vs. $0.18 expected, ARCALYST revenue rose 56% YoY to $214.3M, 2026 ARCALYST revenue guidance was raised to $930M-$945M, and the stock is trading near 52-week highs. | Active | +0.0% |